Contact

Our portfolio

Skyline Dx

Skyline Dx is a molecular diagnostics company focusing on oncology and infectious diseases. Their platform-agnostic tests range from PCR to Next Generation Sequencing technologies. Skyline Dx partners with discovery and commercial companies to develop and distribute their diagnostic tests. The company is dedicated to advancing precision medicine through innovative molecular diagnostics.

  • Institute: Amsterdam UMC
Industry: Diagnostics, Oncology
  • Founding year: 2013
Visit website

Want to get in contact about Skyline Dx?

We’re happy to connect. Reach out to our investment manager working with the team to learn more or explore potential opportunities.

Browse all investment managers

Marc Roelofs

Life Science & Health

Our portfolio

Check out similar ventures

TrianecT
Innovating stroke diagnosis with an AI-powered portable EEG for use inside the ambulance.
Arthrogen
Developing local gene therapy for chronic diseases, Arthrogen utilizes viral-mediated gene transfer to treat conditions like rheumatoid arthritis.
Parkinnova Therapeutics
Developing novel treatments for Parkinson’s disease and dopamine disorders.
Primagen
Investing in and developing molecular diagnostics for biotech innovation.
TrianecT
Innovating stroke diagnosis with an AI-powered portable EEG for use inside the ambulance.
Arthrogen
Developing local gene therapy for chronic diseases, Arthrogen utilizes viral-mediated gene transfer to treat conditions like rheumatoid arthritis.
Parkinnova Therapeutics
Developing novel treatments for Parkinson’s disease and dopamine disorders.
Primagen
Investing in and developing molecular diagnostics for biotech innovation.
Explore full AAV portfolio
Contact